Founded Year

2020

Stage

Series B | Alive

Total Raised

$100M

Revenue

$0000 

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

-170 points in the past 30 days

About BioMap

BioMap focuses on leveraging artificial intelligence (AI) to advance life sciences. The company develops AI foundation models to understand and predict biological behaviors and creates task models for various life science applications, including therapeutic antibodies and industrial enzymes. BioMap primarily serves the biotechnology and pharmaceutical industries with its AI-driven solutions. It was founded in 2020 and is based in Palo Alto, California.

Headquarters Location

2460 Embarcadero Way Suite A

Palo Alto, California, 94303,

United States

810-564-5796

Loading...

ESPs containing BioMap

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTH ➡MARKET STRENGTH ➡LEADERHIGHFLIEROUTPERFORMERCHALLENGER
Healthcare & Life Sciences / Drug R&D Tech

The AI protein engineering platforms market includes computational platforms that leverage AI/ML to design and optimize proteins and peptides for therapeutic purposes or as therapeutic targets. These solutions combine structural biology insights with deep learning to predict protein folding, engineer desired properties, and accelerate drug development. Key capabilities include in silico protein de…

BioMap named as Leader among 15 other companies, including Ginkgo Bioworks, Cradle, and Arzeda.

BioMap's Products & Differentiators

    BP-001

    Pan-solid tumors

Loading...

Expert Collections containing BioMap

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

BioMap is included in 5 Expert Collections, including Digital Health.

D

Digital Health

12,122 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.

D

Drug Discovery Tech Market Map

221 items

This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.

E

Early-Stage Pharma Market Map

82 items

A

Artificial Intelligence (AI)

20,629 items

A

AI in drug discovery

528 items

Companies using AI to advance therapeutic discovery, categorized into: platforms (primary product is software) and discovery engines (primary product is therapeutics). Additional funnel descriptions reflect how companies are applying AI.

Latest BioMap News

China Recap | The nation's AI drive

Oct 6, 2025

China's corporate globalization strategy is evolving fast. Industry giants are rewriting the global playbook, while a new generation of companies charts fresh paths overseas. China Recap tracks both—focusing on strategic expansion, brand building, and localized operations—to help readers make sense of shifting trends and understand how Chinese firms are reshaping their global approach. This edition examines the scope of China's artificial intelligence drive, as markets and infrastructure lead the way while new applications reshape industries from healthcare to entertainment. Chinese AI firms dominate global Q3 gains Chinese AI-related firms dominated markets in the third quarter, accounting for half of the top 20 global gainers by market capitalization. Foxconn Industrial Internet, Eoptolink, and Zhongji Innolight nearly tripled in value, while chipmaker Cambricon more than doubled to USD 77.8 billion. Investors are betting on China's AI drive, though some warn of speculative excess. — Nikkei Asia Biomap claims edge over AlphaFold Biomap, a biotechnology startup co-founded by Baidu's Robin Li and backed by Hong Kong's government, said it has surpassed AlphaFold in commercializing AI models for drug discovery. CEO Wei Liu cited rising pharmaceutical adoption as Biomap expands through BioGend Science, a Hong Kong-based venture aiming to bring drugs to clinical trials within two years. — SCMP Z.ai releases open-source GLM-4.6 Z.ai, formerly Zhipu AI, has released GLM-4.6, an open-source large model with enhanced agentic coding and expanded deployment options. The release marks the first FP8 and Int4 quantization integration on Cambricon chips and also runs with native FP8 precision on Moore Threads GPUs via the vLLM inference framework. — 36Kr Huawei plans to double chip output in 2026 Huawei plans to double production of its Ascend AI chips in 2026, targeting 600,000 units of the 910C model and up to 1.6 million dies across the lineup, according to people familiar with the matter. The ramp-up suggests Huawei and Semiconductor Manufacturing International Corporation (SMIC) are easing bottlenecks under US sanctions as Chinese firms seek alternatives to Nvidia — Bloomberg Moore Threads cleared for Shanghai listing Chinese GPU maker Moore Threads has reportedly won approval for an IPO on Shanghai's STAR Market, less than three months after filing. Founded in 2020 by former Nvidia executive Zhang Jianzong, the Beijing-based company plans to raise RMB 8 billion (USD 1.1 billion) to fund AI chip R&D. Blacklisted by the US in 2023, Moore Threads is part of China's broader effort to bolster semiconductor self-sufficiency. — SCMP AI-generated content gains ground in China Chinese media groups including Tencent , iQiyi, and TVB are expanding use of AI-generated content. iQiyi has launched an “AI theater” with Oscar-winning cinematographer Peter Pau, Tencent is hosting an “AI short film competition,” and TVB has released Hong Kong's first miniseries featuring AI-generated characters. Analysts expect China's AI video systems to generate up to USD 1 billion in annual revenue by 2025. — SCMP That wraps up this edition of China Recap. If your company is expanding internationally, we'd love to hear about your latest milestones. Get in touch to share your story.

BioMap Frequently Asked Questions (FAQ)

  • When was BioMap founded?

    BioMap was founded in 2020.

  • Where is BioMap's headquarters?

    BioMap's headquarters is located at 2460 Embarcadero Way, Palo Alto.

  • What is BioMap's latest funding round?

    BioMap's latest funding round is Series B.

  • How much did BioMap raise?

    BioMap raised a total of $100M.

  • Who are the investors of BioMap?

    Investors of BioMap include Hong Kong Investment Management, Legend Capital, Baidu, Xiang He Capital, Robin Li and 5 more.

  • Who are BioMap's competitors?

    Competitors of BioMap include Atomwise, Iktos, Insilico Medicine, CytoReason, Envisagenics and 7 more.

  • What products does BioMap offer?

    BioMap's products include BP-001 and 4 more.

Loading...

Compare BioMap to Competitors

Healx Logo
Healx

Healx focused on drug discovery in the healthcare sector. The company specializes in developing treatments for rare diseases by leveraging artificial intelligence and drug development expertise. Healx was formerly known as Healx3. It was founded in 2014 and is based in Cambridge, United Kingdom.

Insitro Logo
Insitro

Insitro is a data-driven drug discovery and development company that utilizes machine learning and high-throughput biology. The company has a machine learning platform that combines in vitro cellular data with human clinical data to identify insights and interventions in metabolism, oncology, and neuroscience. Insitro's approach uses technology to model disease states and design therapeutic interventions. It was founded in 2018 and is based in South San Francisco, California.

Atomwise Logo
Atomwise

Atomwise develops machine learning-based discovery engines and uses artificial intelligence (AI)-based neural networks to help discover new medicines. It predicts drug candidates for pharmaceutical companies, start-ups, and research institutions, and designs drugs using computational drug design. It was formerly known as Chematria. The company was founded in 2012 and is based in San Francisco, California.

Isomorphic Laboratories Logo
Isomorphic Laboratories

Isomorphic Laboratories serves as a digital biology company operating in the pharmaceutical and artificial intelligence sectors. The company's main service is to use artificial intelligence, specifically machine learning, to transform and expedite the drug discovery process. The company primarily serves the pharmaceutical industry. It was founded in 2021 and is based in London, United Kingdom.

Terray Therapeutics Logo
Terray Therapeutics

Terray Therapeutics is a biotechnology company that focuses on the discovery and development of small molecule therapeutics. The company offers a platform that integrates ultra-high throughput experimentation with generative AI to improve drug discovery processes. Terray Therapeutics primarily serves the pharmaceutical and biotechnology sectors, using its platform to work with companies on various therapeutic targets. It was founded in 2018 and is based in Monrovia, California.

PharmCADD Logo
PharmCADD

PharmCADD is a company involved in drug discovery using technologies in the pharmaceutical sector. The company's main offerings include a platform that integrates artificial intelligence, molecular dynamics, and quantum mechanics for the design and discovery of drug candidates. PharmCADD also has an mRNA vaccine platform, PharmVAC, which focuses on treatment effects for patients. It was founded in 2019 and is based in Busan, South Korea.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.